Masaru Narabayashi

3.4k total citations
96 papers, 2.6k citations indexed

About

Masaru Narabayashi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiation. According to data from OpenAlex, Masaru Narabayashi has authored 96 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 22 papers in Radiation. Recurrent topics in Masaru Narabayashi's work include Advanced Radiotherapy Techniques (16 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Cancer Treatment and Pharmacology (14 papers). Masaru Narabayashi is often cited by papers focused on Advanced Radiotherapy Techniques (16 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Cancer Treatment and Pharmacology (14 papers). Masaru Narabayashi collaborates with scholars based in Japan, United States and United Kingdom. Masaru Narabayashi's co-authors include Yukinori Matsuo, Takashi Mizowaki, Masahiro Hiraoka, Yoshiki Norihisa, Noriyuki Katsumata, Yasushi Nagata, Toru Watanabe, Kensei Tobinai, Masashi Ando and Yasutsuna Sasaki and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Masaru Narabayashi

94 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masaru Narabayashi Japan	28	1.0k	881	502	460	338	96	2.6k
Mison Chun South Korea	28	876 0.9×	510 0.6×	244 0.5×	105 0.2×	292 0.9×	160	2.6k
Shigemitsu Takashima Japan	30	1.6k 1.6×	1.1k 1.2×	640 1.3×	29 0.1×	435 1.3×	158	3.4k
John W. Kugler United States	32	2.6k 2.6×	1.4k 1.6×	115 0.2×	58 0.1×	703 2.1×	62	4.5k
Stephen Frytak United States	31	1.9k 1.9×	1.4k 1.6×	194 0.4×	37 0.1×	627 1.9×	113	3.7k
Seppo W. Langer Denmark	33	2.8k 2.8×	830 0.9×	465 0.9×	39 0.1×	284 0.8×	202	4.2k
Albert Biete Spain	21	540 0.5×	357 0.4×	361 0.7×	95 0.2×	261 0.8×	81	1.6k
Joshua Bauml United States	29	2.3k 2.2×	1.7k 1.9×	198 0.4×	45 0.1×	527 1.6×	140	3.3k
Takeo Takahashi Japan	22	413 0.4×	531 0.6×	219 0.4×	147 0.3×	326 1.0×	147	1.8k
Johannes M.G. Bonfrèr Netherlands	33	1.4k 1.4×	994 1.1×	235 0.5×	507 1.1×	1.1k 3.4×	67	4.1k
Albert S. DeNittis United States	19	663 0.7×	1.1k 1.3×	367 0.7×	176 0.4×	99 0.3×	52	1.9k

Countries citing papers authored by Masaru Narabayashi

Since Specialization

Citations

This map shows the geographic impact of Masaru Narabayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaru Narabayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaru Narabayashi more than expected).

Fields of papers citing papers by Masaru Narabayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaru Narabayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaru Narabayashi. The network helps show where Masaru Narabayashi may publish in the future.

Co-authorship network of co-authors of Masaru Narabayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Masaru Narabayashi. A scholar is included among the top collaborators of Masaru Narabayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaru Narabayashi. Masaru Narabayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shintani, Takashi, Yukinori Matsuo, Masakazu Ogura, et al.. (2021). Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab. Clinical Lung Cancer. 22(5). 401–410. 34 indexed citations

Katakami, Nobuyuki, Toshiyuki Harada, Katsunori Shinozaki, et al.. (2018). Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Annals of Oncology. 29(6). 1461–1467. 37 indexed citations

Iwata, Hiroji, Masaru Narabayashi, Yoshinori Ito, et al.. (2012). A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. International Journal of Clinical Oncology. 18(4). 621–628. 16 indexed citations

Ueki, N., Yukinori Matsuo, Keiko Shibuya, et al.. (2012). Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer. Journal of Radiation Research. 54(2). 337–343. 10 indexed citations

Araki, Kazuhiro, Hirofumi Mukai, Toru Mukohara, et al.. (2011). First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors. Investigational New Drugs. 30(6). 2327–2333. 3 indexed citations

Ito, Hiroshi, Makoto Wada, Makoto Wada, et al.. (2011). Drug-induced akathisia as a cause of distress in spouse caregivers of cancer patients. Palliative & Supportive Care. 9(2). 209–212. 2 indexed citations

Norihisa, Yoshiki, Takashi Mizowaki, Kenji Takayama, et al.. (2011). Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol. International Journal of Clinical Oncology. 17(5). 505–511. 23 indexed citations

Fujita, Ken‐ichi, Wataru Ichikawa, Wataru Yamamoto, et al.. (2009). Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. Annals of Oncology. 20(5). 946–949. 4 indexed citations

Nakamura, Mitsuhiro, Yuichiro Narita, Yukinori Matsuo, et al.. (2009). Effect of Audio Coaching on Correlation of Abdominal Displacement With Lung Tumor Motion. International Journal of Radiation Oncology*Biology*Physics. 75(2). 558–563. 21 indexed citations

10.

Narabayashi, Masaru, Yoshifumi Saijo, Seiichi Takenoshita, et al.. (2008). Opioid Rotation from Oral Morphine to Oral Oxycodone in Cancer Patients with Intolerable Adverse Effects: An Open-Label Trial. Japanese Journal of Clinical Oncology. 38(4). 296–304. 46 indexed citations

11.

Nakamura, Mitsuhiro, Yuichiro Narita, Yukinori Matsuo, et al.. (2008). Correlative analysis of abdominal motion with lung tumor motion for non-invasive respiratory gated radiotherapy. 20(3). 119–125. 1 indexed citations

12.

Sunakawa, Yu, Makoto Wada, Tomomi Nishida, et al.. (2008). A case of respiratory akathisia in a cancer patient: A case report. Palliative & Supportive Care. 6(1). 79–81. 3 indexed citations

13.

Fujita, Ken‐ichi, Wataru Yamamoto, H. Endo, et al.. (2007). Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1. Journal of Clinical Oncology. 25(18_suppl). 2504–2504. 2 indexed citations

14.

Fujita, Ken‐ichi, Yukio Ando, Masaru Narabayashi, et al.. (2005). GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN. Drug Metabolism and Disposition. 33(12). 1785–1790. 15 indexed citations

15.

Ando, Koji, Yoshihiro Matsuno, Yae Kanai, et al.. (1999). Primary Low-grade Lymphoma of Mucosa-associated Lymphoid Tissue of the Urinary Bladder: a Case Report with Special Reference to the Use of Ancillary Diagnostic Studies. Japanese Journal of Clinical Oncology. 29(12). 636–639. 9 indexed citations

16.

Tobinai, Kensei, Yukio Kobayashi, Masaru Narabayashi, et al.. (1998). Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Annals of Oncology. 9(5). 527–534. 126 indexed citations

17.

Yamamoto, Nobuyuki, Noriyuki Katsumata, Toru Watanabe, et al.. (1998). Clinical Characteristics of Patients with Metastatic Breast Cancer with Complete Remission Following Systemic Treatment. Japanese Journal of Clinical Oncology. 28(6). 368–373. 17 indexed citations

18.

Katsumata, Noriyuki, Yoshihiro Matsuno, H. Nakayama, et al.. (1996). Prognostic Factors and a Predictive Model of Follicular Lymphoma: A 25-year Study at a Single Institution in Japan. Japanese Journal of Clinical Oncology. 26(6). 445–454. 13 indexed citations

19.

Tobinai, Kensei, Akio Kohno, Yasuhiro Shimada, et al.. (1993). Toxicity Grading Criteria of the Japan Clinical Oncology Group. Japanese Journal of Clinical Oncology. 23(4). 250–257. 161 indexed citations

20.

Narabayashi, Masaru, Kunihiko Maeda, Mikio Matsuda, & Yutaka Imai. (1990). Immunohistological study in the distribution and function of follicular dendritic cell(FDC) in follicular lymphoma.. 30(4). 333–353. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact